Author(s):
Marques da Silva, P ; Sequeira Duarte, J ; von Hafe, P ; Gil, V ; Nunes de Oliveira, J ; de Sousa, G
Date: 2018
Persistent ID: http://hdl.handle.net/10400.17/3015
Origin: Repositório do Centro Hospitalar de Lisboa Central, EPE
Subject(s): HSM MED; Atherosclerosis/etiology; Atherosclerosis/prevention & control; Cardiovascular Diseases/etiology; Cardiovascular Diseases/prevention & control; Clinical Laboratory Techniques/standards; Consensus Development Conferences as Topic; Dyslipidemias/blood; Dyslipidemias/complications; Lipids/blood; Practice Guidelines as Topic
Description
Even with improvements in lifestyle interventions, better control of cardiovascular (CV) risk factors, and improvements in CV outcomes, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in Portugal and Europe. Atherogenic dyslipidemias, particularly hypercholesterolemia, have a crucial causal role in the development of atherosclerotic CVD. The clinical approach to a patient with dyslipidemia requires an accurate diagnosis, based on harmonized and standardized lipid and lipoprotein laboratory assessments. Results and reports of these tests, together with assessment of total CV risk and the respective therapeutic targets, will help ensure that clinical guidelines and good clinical practices are followed, increasing the reliability of screening for lipid disorders, producing more accurate diagnoses and CV risk stratification, and improving CV prevention. To this end, this consensus aims to provide clinicians with practical guidance for the harmonization and standardization of laboratory lipid tests, focusing on the most recent dyslipidemia management guidelines.
